Table 1 |
|||
|
Clinical data of patients |
|||
| n = 254 |
BM positive (%) |
p-value* |
|
|
|
|||
| Total |
254 |
107 (42) |
|
| Menopausal status |
|||
| Premenopausal |
79 |
33 (42) |
0.94 |
| Postmenopausal |
175 |
74 (42) |
|
| Tumour size |
|||
| pT1 |
148 |
60 (41) |
0.77 |
| pT2-4 |
103 |
46 (45) |
|
| Nodal status |
|||
| Node negative |
149 |
62 (42) |
0.88 |
| Node positive |
101 |
43 (43) |
|
| Histology |
|||
| Ductal |
177 |
74 (42) |
0.12 |
| Lobular |
57 |
21 (37) |
|
| Others |
17 |
11 (65) |
|
| Grading |
|||
| I to II |
217 |
91 (42) |
0.85 |
| III |
32 |
14 (44) |
|
| ER status |
|||
| Negative |
42 |
19 (45) |
0.83 |
| Positive |
208 |
88 (42) |
|
| PR status |
|||
| Negative |
69 |
26 (38) |
0.39 |
| Positive |
181 |
79 (44) |
|
| HER2 |
|||
| Negative (0/+1) |
211 |
94 (45) |
0.08 |
| Positive (+2/+3) |
32 |
9 (28) |
|
|
|
|||
|
* by Chi-squared test. BM = bone marrow; ER = oestrogen receptor; HER2 = human epidermal growth factor receptor 2; PR = progesterone receptor. |
|||
|
Fehm et al. Breast Cancer Research 2008 10:R76 doi:10.1186/bcr2143 |
|||
